ASTH

Astrana Health, Inc. (ASTH) - Q3 2025 10-Q Summary

Business Context and Reporting Period

This report covers the quarterly period ended September 30, 2025. Astrana Health, Inc. is a provider-centric, technology-powered, risk-bearing healthcare company operating through three segments: Care Partners, Care Delivery, and Care Enablement. The period was significantly impacted by the acquisition of certain assets and businesses of Prospect Medical Holdings, Inc. ("Prospect") on July 1, 2025, for a purchase price of $674.9 million. This transaction expanded the company's provider network to over 11,000 providers and increased the managed patient population to over 1.6 million.

Key Financial Metrics

Material Changes vs. Prior Period

• Revenue Growth: Revenue doubled in Q3 2025 (+100%) and increased 63% for the nine months ended September 30, 2025. The Q3 increase was driven by the Prospect acquisition, which contributed approximately $308.0 million in revenue since the July 1 closing date.
• Profitability Decline: Despite revenue growth, Net Income attributable to Astrana dropped 98% in Q3 and 67% for the nine-month period compared to 2024. This was primarily due to increased interest expense from debt financing the acquisition, higher depreciation and amortization, and a $13.0 million legal charge related to an arbitration proceeding with a provider associated with CFC Health Plan, Inc.
• Debt Expansion: Total debt increased to $1.064 billion from $438.1 million at year-end 2024. The company drew $707.3 million on a delayed draw term loan to fund the Prospect acquisition.
• Segment Performance: The Care Partners segment saw revenue surge but operating income decline due to the legal charge. The Care Enablement segment saw operating income increase by 271% in Q3, driven by the acquisition.

Guidance, Outlook, and Risks

• Regulatory Impact: The "One Big Beautiful Bill Act" (OBBBA), signed July 4, 2025, introduces Medicaid work-requirement pilots and tighter provider-tax rules. Management anticipates reduced tax payables but warns of potential reductions in patient population and managed care enrollees due to stricter eligibility requirements.
• Bankruptcy Risk: On July 7, 2025, certain Prospect asset seller entities filed for Chapter 11 bankruptcy. While the asset sale transaction may shield Astrana from third-party liabilities, the company faces risks of absorbing costs related to breaches of contractual obligations by the sellers, with limited recourse.
• Liquidity: Management believes it has sufficient liquidity to fund operations for at least the next 12 months. Working capital decreased to $253.7 million from $272.9 million at year-end 2024.
• Legal Contingency: The $13.0 million charge recorded in Q3 relates to an ongoing arbitration. The company plans to seek reimbursement from an escrow account established during the AHMS acquisition.

Investor Verification Checklist

• Prospect Integration: Verify the timeline and success of integrating Prospect's 11,000+ providers and the realization of projected synergies.
• Legal Exposure: Monitor the status of the CFC Health Plan arbitration and the potential for additional costs beyond the $13.0 million charge.
• Debt Servicing: Assess the impact of the increased debt load ($1.06B) and interest rates (5.91%) on future cash flows and compliance with leverage covenants (max 5.00x until March 2027).
• Regulatory Headwinds: Evaluate the specific impact of the OBBBA on Medicaid enrollment and provider tax revenues, particularly for the newly acquired Foothill Regional Medical Center.
• Bankruptcy Fallout: Confirm that the bankruptcy of Prospect seller entities does not result in unexpected liabilities or operational disruptions.